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Introduction: S-1 is a rationally designed oral agent that combines
the 5-fluorouracil prodrug tegafur with gimeracil and oteracil, which
inhibit 5-fluorouracil degradation by dihydropyrimidine dehydro-
nase and phosphorylation within the gastrointestinal tract, respec-
tively, to increase antineoplastic activity while reducing gastrointes-
tinal toxicity. We investigated the activity and toxicity of S-1 in
combination with cisplatin in patients with unresectable non-small
cell lung cancer (NSCLC).
Methods: Cisplatin, 75 mg/m2, was administered intravenously on
day 1, with S-1, 25 mg/m2 PO two times a day, days 1 to 14, every
21 days for a maximum of six cycles. Primary end point was overall
response.
Results: A total of 58 patients received at least one cycle of
protocol-specified therapy. The best overall response rate was 23.2%
(95% confidence interval: 13.0–36.4), and the disease control rate
was 67.9%. The median progression-free survival was 4.0 months
(95% confidence interval: 3.3–5.5). There did not appear to be any
relationship between response to therapy and tumor histology. The
most frequently reported adverse events of G3 or more (10%)
were neutropenia (28%), hyponatremia (19%), diarrhea (17%), hy-
pokalemia (12%), fatigue (10%), dehydration (10%), and deep vein
thrombosis (10%).
Conclusions: Although the S-1  cisplatin regimen used in this
study appeared to have a similar level of antitumor activity and
toxicity to that of established cisplatin-based doublets in NSCLC,
the protocol-specified criteria of sufficient efficacy to warrant further
study with an objective response rate 30% was not achieved.
Therefore, while S-1 appears to be a promising agent in NSCLC,
further evaluation should be conducted to determine the optimal
S-1-based regimen to take forward for additional study.
Key Words: Lung cancer, Non-small cell, S-1, Cisplatin, Fluoro-
pyrimidines, Clinical trial.
(J Thorac Oncol. 2011;6: 1400–1406)
Lung cancer is the second most common form of cancerand the leading cause of cancer death in both men and
women in the United States. Data from the American
Cancer Society projected more than 219,440 new cases of
lung cancer in 2009.1 Lung cancer is still a highly lethal
malignancy in both genders, with a 5-year survival rate
that is less than 15%.
Chemotherapy for stage IV non-small cell lung cancer
(NSCLC) is still suboptimal, and for all intents and purposes,
metastatic lung cancer remains incurable. The currently ac-
cepted frontline therapy for unresectable NSCLC is platinum-
based doublet therapy with or without biological com-
pounds.2 The standard of care for most “fit” patients is a
combination of cisplatin or carboplatin with a taxane (pacli-
taxel or docetaxel), vinorelbine, a topoisomerase inhibitor
(irinotecan or topotecan), pemetrexed, or gemcitabine.3 How-
ever, in multiple randomized multi-institutional trials, each of
the doublets has a comparable response rate of approximately
20%, median progression-free survival (PFS) of 4 to 5
months, median overall survival of 8 to 10 months, and
1-year survival of 35 to 40%. Toxicities, although manage-
able, can be considerable, including myelosuppression and
neutropenic fever, neuropathy, and gastrointestinal toxicities.
Recently, with an appreciation of the influence of histology
on response and survival associated with certain regimens, a
modest improvement (median survival of 12 months) has
been observed with the addition of the vascular endothelial
growth factor inhibitor bevacizumab to platinum-based ther-
apy in nonsquamous carcinomas, and the utilization of pem-
etrexed was limited to the same patient population.4 While
this modest progress is encouraging, it is clear that other
agents and regimens must be evaluated.
5-Fluorouracil (5-FU), one of the most underutilized
antineoplastic agents, has minimal activity against NSCLC,
potentially due to an overexpression of dihydropyrimidine
dehydronase (DPD).5,6 The most recent studies have evalu-
ated bolus infusions of 5-FU, usually in combination with
other agents such as cisplatin and etoposide or a vinca
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alkaloid, or radiotherapy.7–11 Single agent 5-FU is modestly
active in combination with leucovorin, with a 16% objective
response rate noted in one study.9 Although 5-FU may be
more active when administered continuously, prolonged in-
fusion is cumbersome for most patients. To date, there have
only been a few prior reports of the oral fluoropyrimidine,
tegafur and uracil, and capecitabine administered to patients
with NSCLC.11–16
S-1 is a novel oral fluoropyrimidine that combines
tegafur (5-fluoro-1-[tetrahydro-2-furyl]uracil), a prodrug of
5-FU, with two modulators, gimeracil (5-chloro-2,4-dihy-
droxypyridine, CDHP), which inhibits 5-FU degradation by
DPD inhibition, and oteracil potassium (monopotassium
1,2,3,4-tetrahydro-2,4-dioxo-1,3,5-triazine-6-carboxylate),
which inhibits 5-FU phosphorylation in the digestive tract
(Figure 1).17 CDHP is about 180 times more potent than
uracil in inhibiting DPD in both the tumor and the liver, thus
allowing greater concentrations of 5-FU to go though the
anabolic pathway than that of tegafur and uracil alone.18 S-1
is rationally designed to achieve enhanced antitumor activity
while decreasing gastrointestinal tract toxicity. S-1 is cur-
rently marketed in Japan, South Korea, China, and Singapore
for the treatment of cancers of the stomach. In Japan, phase II
trials of S-1 have shown promising efficacy (response rate:
33–47%, median survival time: 11–16 months) and tolera-
bility as first-line chemotherapy for patients with advanced
NSCLC.19,20 Based on evidence of benefit in prior studies,
and as the ultimate outcome of systemic therapy in NSCLC is
still poor, we investigated a combination of S-1 with cisplatin
in patients with advanced NSCLC.
MATERIALS AND METHODS
Study Design
This was an open-label, multicenter, single-arm, three-
stage, phase II study evaluating the efficacy and safety of S-1
in combination with cisplatin in patients who have not re-
ceived any prior therapy for advanced NSCLC. The three
stages of this study corresponded to a run-in tolerability stage
(stage 1), a futility stage (stage 2), and a decision stage (stage
3). The run-in tolerability stage was conducted at a limited
number of sites to assess any additional toxicity associated
with a more frequent schedule of administration of cisplatin
(75 mg/m2 every 3 weeks) versus the dosing regimen estab-
lished in a prior phase I study in patients with advanced
gastric cancer (75 mg/m2 every 4 weeks).21 Stage 2 was
conducted to ensure that the treatment combination was
sufficiently efficacious to expose a sufficient number of
patients to be able to make a decision (stage 3) whether this
combination treatment warranted further evaluation in future
studies.
Eligibility
All patients were required to have a histologic or
cytologic diagnosis of NSCLC that was either locally ad-
vanced but not amenable to treatment with radiotherapy or
surgery or metastatic disease. Mixed small cell and non-small
cell histologies were not allowed. Other eligibility criteria
included an Eastern Cooperative Oncology Group (ECOG)
performance status 0 to 1; age 18 years or older; using
effective contraception; and have evidence of good end-organ
function (absolute neutrophil count 1500/l, platelet count
100,000/l, calculated creatinine clearance 60 ml/min,
and bilirubin 1.5  normal). Patients were excluded if they
were either pregnant or lactating; had a myocardial infarction;
had other active malignancy; had prior chemotherapy for
metastatic disease (prior chemotherapy for adjuvant or neo-
adjuvant therapy was allowed provided it was completed at
least 12 months earlier); had prior radiotherapy to an indica-
tor lesion unless there was objective evidence of tumor
growth in that lesion; had evidence of uncontrolled symp-
tomatic metastatic disease of the central nervous system; had
received either radiotherapy or surgery within 2 weeks; had
any investigational agent, either currently or within the past
FIGURE 1. Components of S-1 and
role in the metabolism of 5-fluorou-
racil.
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30 days; or had any comorbid condition that, in the view of
the attending physician, might place the patient at an in-
creased risk for treatment complications. All patients were
required to provide signed informed consent.
Treatment Plan
Study Evaluations
Within 1 week of the initiation of therapy, all patients
were required to undergo a baseline evaluation, including a
medical history and physical examination, complete blood
count with leukocyte differential, and serum chemistries. A
computed tomography or magnetic resonance imaging scan
for tumor measurement was to be obtained within 4 weeks of
therapy. Blood counts were repeated weekly during each
cycle, along with the serum chemistries, before each cycle.
Repeat radiographic evaluation was performed before every
other cycle until the observation of progressive disease (PD)
to document tumor response.
Chemotherapy Guidelines
All patients received S-1, 25 mg/m2, administered
orally twice daily from days 1 through 14, and cisplatin, 75
mg/m2, administered intravenously (IV) as a 1- to 3-hour
infusion on day 1 of each cycle after the morning dose of S-1.
A recovery period followed on days 15 through 21. This
regimen was repeated every 3 weeks for a maximum of six
cycles.
Determination of Toxicity and Response
All patients were eligible for evaluation of toxicity,
even if they were unable to complete the first cycle. Patients
were monitored for safety using adverse event (AE) informa-
tion, physical examinations, the ECOG scale, vital signs, and
laboratory evaluations. AEs were graded using National Can-
cer Institute (NCI) Common Toxicity Criteria version 3.0
(CTC v3.0).
On-site tumor assessments were performed by the in-
vestigator and local radiologist, and the results of those
assessments were used to determine whether to continue or
discontinue treatment. Tumor scans were collected and for-
warded to the Core Imaging Laboratory (ICON Medical
Imaging) for independent reader review. Scans/assessments
were collected on an end of every even-cycle schedule;
however, if a patient responded, response confirmation was to
be obtained through tumor assessments/scans at least 4 weeks
after the first documentation of response. Patients then re-
turned to their original even-cycle schedule of assessments.
The same schedule was followed for clinical assessments;
however, if the patient developed PD during clinic visits,
study treatment was discontinued. After discontinuation of
study treatment for reasons other than withdrawal of consent
or PD, patients were followed for tumor response every 6
weeks until disease progression or initiation of new antican-
cer therapy. Treatment decisions by the investigator were
based on objective tumor assessments made according to the
RECIST criteria of unidimensional evaluation. The determi-
nation of antitumor efficacy, as determined by an independent
reader, was also based on those criteria.
Statistical Considerations
Study Design
This study was designed as an exploratory, proof of
concept study in three stages to evaluate the tolerability and
antitumor activity of S-1 in combination with cisplatin in
patients with advanced NSCLC. The study design reflects the
classical two-stage Simon design, with the exception that the
first stage is divided into two parts: (a) the run-in tolerability
stage and (b) the futility stage. The treatment regimen of S-1
25 mg/m2 combined with cisplatin 75 mg/m2 administered on
a 21-day cycle as used in this study was similar to the
maximum tolerated dose of S-1 25 mg/m2 combined with
cisplatin 75 mg/m2 for 4 weeks, which was established in a
phase I dose-escalation study in patients with advanced gas-
tric cancer.21 However, in this study, cisplatin was adminis-
tered every 3 weeks to keep the cisplatin dose intensity in the
21 to 30 mg/m2/wk range, rather than every 4 weeks, as in the
previous study. The run-in tolerability stage assessed any
additional toxicity associated with a more frequent schedule
of administration of cisplatin.
In this study, a response rate of 35% or higher would be
considered as a good indicator for further development,
whereas a response rate of 20% or lower would be considered
poor and not supportive of future development. Based on the
exact binomial probability distribution approach published by
Richard Simon,22 the sample size would be 53 for a “Mini-
max Design” with P1  0.35, P0  0.20, with   0.05 (one
sided),   0.2. For the first and second stage combined, the
sample size would be 31. The trial could go on to the third
stage only if 7 of 31 (23%) or more patients had achieved a
confirmed response (complete response [CR] or partial re-
sponse [PR]) in the first two stages. To be considered suffi-
ciently efficacious to warrant further study, the criteria to
proceed to stage 3 needed to be met and, by the end of the
trial, there needed to be 16 of 53 patients (30%) or more who
had achieved a confirmed response. Simon’s “Minimax De-
sign” was chosen over his “Optimal Design,” as it minimized
the maximum sample size when the criteria for proceeding to
the second stage were met, which was the expectation based
on S-1 performance in studies previously conducted in United
States and Japan. Assuming a 10% rate for loss to follow-up
and/or nonevaluability for the response rate assessment, it
was projected that a total of 60 patients would be enrolled in
the study. The primary end point, overall response rate
(ORR), was used as a screening end point in this exploratory,
proof of concept study in patients with advanced NSCLC.
Efficacy. The primary efficacy population included all pa-
tients in the safety population who met the key eligibility
criteria. All efficacy parameters were analyzed using data
from this population, including the primary efficacy end
point, ORR, based on the best overall response for each
patient. For ORR, the determination of an efficacious result
was based on the two-stage “Minimax” methodology de-
scribed by Richard Simon (i.e., there must be 30% or more
patients who achieved a confirmed response to be considered
efficacious at the end of the study).
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The time to the first CR or PR, the duration of the CR or
PR, and PFS were estimated using Kaplan-Meier methodology.
Safety. Hematology were assessed weekly, and blood bio-
chemistry, urinalysis, and physical findings/vital signs were
assessed triweekly. Other safety data (vital signs, ECOG
performance status, and clinical laboratory results) were sum-
marized descriptively. Any AEs were evaluated for grading,
duration, and S-1 causality according to the NCI-CTC v3.0.
RESULTS
Patient Demographics
A total of 60 patients were enrolled, of which 58
received the study drug. Two patient discontinued before
treatment due to AE. The majority of the patients were white
(46 of 58, 79%) (Table 1). More than half of the patients (34
of 58, 59%) had histologic/cytologic classification of adeno-
carcinoma. Fifty-two patients (90%) had stage IV NSCLC,
and 6 (10%) had stage IIIB NSCLC. At study entry, approx-
imately 60% of patients had an ECOG performance status of
1, while the remainder had ECOG scores of 0. Most patients
(51 of 58, 88%) had not had prior resections. Seventeen of 58
(29%) patients had prior radiotherapy; none of the patients
had received systemic anticancer therapy before study entry.
Among the 58 treated patients, at baseline, 57 patients had
measurable disease based on the investigator assessment. A
majority of those patients (50 of 57, 88%) had two or more
target lesions at the time of study entry.
Responses to Therapy
The ORR for the first 31 patients (stages 1 and 2) was
36% (11 of 31) by the investigator assessment; therefore, the
study proceeded to stage 3. Based on independent reader
assessments, the best ORR was with 13 patients achieving a
PR, 25 (45%) patients with stable disease, and 14 (25%)
patients with PD, while 4 (7%) patients were not evaluable.
The overall response was 23% (95% CI: 13.0–36.4), and the
disease control rate was 68% (95% CI: 54.0–79.7) (Table 2).
There was no evidence of any interaction of tumor histology
with objective response to therapy, although the study was
not powered to evaluate such potential interactions (Table 2).
A total of 10 patients presented with squamous cell carci-
noma; 2 (20%) experienced a PR on independent review,
while the ORR was 24% (11 of 46) in patients with nons-
quamous cell carcinoma. For those patients responding to
treatment, the median duration of response was 4.2 months
(n  13) based on the independent review assessments. For
all patients, the Kaplan-Meier estimate for median PFS was
4.0 months (95% CI: 3.3–5.5) based on independent review
assessments (Figure 2).
Toxicity
No dose-limiting toxicities were observed for six pa-
tients at stage 1. Therefore, the study proceeded to stage 2. A
total of 58 patients in all stages received at least one dose of
S-1 and were included in the safety population. The median
number of cycles of study treatment delivered was 4. More
than 55% of patients initiated at least four cycles of treatment,
and 36% had all six cycles initiated. Median relative dose
intensity was 0.90 (SD, 0.17; range, 0.38–1.22) for S-1 and
0.94 for cisplatin (SD, 0.17; range, 0–1.03).
All 58 (100%) patients experienced at least one AE
(Table 3). Twenty-four (41%) patients experienced grade 3
AEs and 16 (28%) experienced grade 4 AEs. The most
frequently reported AEs of grade 3 or more (10%) were
neutropenia (28%), hyponatremia (19%), diarrhea (17%),
hypokalemia (12%), fatigue (10%), dehydration (10%), and
deep vein thrombosis (10%). Only one patient (2%) experi-
enced a treatment-related deep vein thrombosis. A total of
TABLE 1. Patient Characteristics (n  58)
n %
Age, years
Median (range) 63.0 (40–84)
Gender, n (%)
Male 37 64
Female 21 36
ECOG PS, n (%)
0 23 40
1 35 60
Race
White 46 79
African American 7 12
Asian 2 3
Other 3 5
BSA, m2
Median (range) 1.86 (1.33–2.30)
Histological classification
Adenocarcinoma 34 59
Squamous cell 10 17
Large cell 3 5
Other 11 19
Stage, TNM classification
Stage IIIB 6 10
Stage IV 52 90
Sites of metastatic disease at baseline
Lymph nodes 42 72
Lung 30 52
Liver 14 24
Bone 21 36
CNS 3 5
Other 20 35
Number of target lesions
1 7 12
2 16 28
3 12 21
3 22 39
Prior surgery
Not resected 51 88
Partially resected 1 2
Resected 6 10
Prior radiotherapy
Yes 17 29
No 41 71
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three patients died due to treatment-related AEs that occurred
at any time during the study (including events with onset30
days after the last dose of study drug): neutropenic sepsis and
multiorgan failure (one patient), renal failure (one patient),
and sepsis and multiorgan failure (one patient). Twenty-two
of the 58 (38%) patients discontinued their study participation
due to objective disease progression. Remaining patients
discontinued the study due to completion of all six cycles of
study-specified treatment (28%), AEs (14%), investigator
judgment (9%), noncompliance (3%), death (3%), requiring
more than 3 weeks to recover from a prior treatment cycle
(2%), intercurrent illness (2%), or other reasons (2%).
DISCUSSION
Disseminated NSCLC remains a frustrating disease to
treat, with poor responses to treatment in most of the patients.
Although treatment with chemotherapy may offer some pal-
liative benefit, the survival benefit of platinum-based chemo-
therapy, still considered the “gold standard,” is modest and
measured in weeks. We need to identify and evaluate new
agents and combinations that may offer improvements in
response rate and survival. Equally important is to identify
regimens that may be equivalent in activity to the current
standard regimens but with less toxicity.
Conventional 5-FU has not provided clinically relevant
responses in most patients with NSCLC. An explanation of
TABLE 2. Response Rate by Independent Assessment
(n  56)
Total
(n  56)
Patients with
Squamous
cell carcinoma
(n  10)
Patients with
Non-squamous
cell carcinoma
(n  46)
Response, n (%)
Complete response 0 (0) 0 (0) 0 (0)
Partial response 13 (23) 2 (20) 11 (24)
Stable disease 25 (45) 4 (40) 21 (46)
Progressive disease 14 (25) 3 (30) 11 (24)
Not evaluable* 4 (7) 1 (10) 3 (7)
Overall response
rate, n (%)
13 (23) 2 (20) 11 (24)
95% CI 13.0–36.4 — —
Disease control
rate, n (%)
38 (67.9) 6 (60.0) 32 (69.6)
95% CI 54.0–79.7 — —
*No post-baseline assessments.
FIGURE 2. Progression-free survival by in-
dependent assessment (n  56).
TABLE 3. Hematological and Non-hematological Adverse
Events
Any >  G3
n % n %
Leukopenia 8 14 3 5
Neutropenia 22 38 16 28
Anemia 30 52 2 3
Thrombocytopenia 7 12 2 3
Anorexia 17 29 1 2
Nausea 42 72 5 9
Vomiting 28 48 4 7
Fatigue 34 59 6 10
Diarrhea 29 50 10 17
Dehydration 15 26 6 10
Stomatitis 6 10 0 0
Constipation 22 38 1 2
Abdominal pain 10 17 3 5
Weight decreased 13 22 2 3
Rash 6 10 0 0
Dizziness 15 26 1 2
Hyponatraemia 15 26 11 19
Hypokalaemia 12 21 7 12
Hypotension 13 22 3 5
Deep Vein Thrombosis 7 12 6 10
Sandler et al. Journal of Thoracic Oncology • Volume 6, Number 8, August 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1404
this failure may be that the majority of patients with NSCLC
have been shown to have relatively high DPD activity.5,6
When 5-FU is administered intravenously alone, 90% of the
drug is rapidly catabolized in the liver by DPD and excreted
in the urine as -fluoro--alanine. S-1 is a new oral pyrimi-
dine fluoride-derived anticancer agent in which tegafur is
combined with two classes of modulators, gimeracil (CDHP)
and oteracil potassium (Oxo). This combination drug is being
developed to enhance the clinical advantage of an oral fluo-
ropyrimidine and ameliorate the disadvantage of gastrointes-
tinal toxicity. Within the patient population with high DPD
activity, more than 60% have been shown to have low
thymidylate synthase (TS) activity while 25% have high TS
activity. Without inhibition of the high DPD activity, con-
ventional 5-FU and 5-FU prodrugs are considered to be
rapidly destroyed, significantly limiting the amount of 5-FU
that is available for the anabolic pathway. Because S-1
contains CDHP, an inhibitor of DPD, catabolism is signifi-
cantly slowed, allowing large amounts of 5-FU to be available
for the anabolic pathway. In fact, two phase II studies with S-1
in patients with NSCLC conducted in Japan demonstrated prom-
ising efficacy with an acceptable safety profile.19,20
Cisplatin is the backbone of treatment regimens for
patients with advanced NSCLC (stage IIIb/stage IV). Cispla-
tin as a single agent has limited antitumor activity. Sandler et
al.23 reported an ORR for cisplatin alone in NSCLC of 11.1%
(CR: 0.4%, PR: 10.7%). The higher ORR observed with
cisplatin  S-1 in this study (23%) underlines that S-1 has an
antitumor effect in patients with advanced NSCLC.
This is one of the first studies in North America to
demonstrate that a fluoropyrimidine has an antitumor effect in
patients with NSCLC; this builds on Japanese experience
with this agent when administered as a single agent or in
combination with cisplatin or irinotecan.24 The prior lack of
efficacy with 5-FU could be explained by the high DPD
activity in NSCLC, as a component of S-1 inhibits the DPD
enzyme and could explain the activity of S-1 in this patient
population. A separate pilot trial by Sagar et al.16 also
demonstrated some potential benefit to a combination of
capecitabine and carboplatin but at dose levels that proved
too toxic for further evaluation. The study results are com-
parable to results obtained using established cisplatin-based
regimens for treatment of patients with advanced NSCLC
(stage IIIb/stage IV). Schiller et al.25 conducted a randomized
trial to compare the efficacy of three commonly used regi-
mens with that of a reference regimen of cisplatin/paclitaxel.
The cisplatin dose in the cisplatin/paclitaxel regimen and the
cisplatin/docetaxel regimen was 75 mg/m2 every 3 weeks, the
same as used in this study. The ORRs using cisplatin with
paclitaxel and cisplatin with docetaxel were 21% and 17%,
respectively. Median time to progression was 3.4 months
(2.8–3.9 months) for cisplatin/paclitaxel and 3.7 months
(2.9–4.2 months) for cisplatin/docetaxel. The primary objec-
tive of this study of an ORR of 30% could not be reached.
One of the reasons for this might be the lower dosage of S-1
in the study compared with that in Japanese studies.20,24,26,27
However, the higher dosage of S-1 (30 mg/m2) was not safe
when combined with cisplatin 75 mg/m2 on day 1 in a phase
I dose-escalation study in patients with advanced gastric
cancer.21 Therefore, we investigated the combination regimen
of the established dosage of S-1 (25 mg/m2) and the standard
dosage of cisplatin (75 mg/m2) in this study. In fact, the
results indicate that the doublet cisplatin  S-1 may have
antitumor activity comparable to that of established cisplatin-
based doublets. Ichinose et al.20 and Kubota et al.26 investi-
gated the regimen of S-1 in combination with cisplatin on day
8, which shows promising results. Therefore, it is necessary
to find the best regimen of S-1  cisplatin combination in a
randomized study in the future.
As with all cisplatin-based regimens, the S-1  cispla-
tin regimen used in this study was associated with significant
toxicity.25,28–32 More than 55% of patients initiated at least
four cycles of treatment, and 36% had six cycles initiated.
Across all cycles, 42% of patients experienced AEs with
maximum grade 3 toxicity, and 28% of patients experienced
AEs with maximum grade 4 toxicity. This overall toxicity is
lower than that observed with the treatment regimens of
cisplatin/paclitaxel or cisplatin/docetaxel, for which maxi-
mum grade 4 toxicity was observed in 68% and 61% of
patients, respectively.25 The most common toxic effect of
platinum-based doublet therapy is bone marrow suppression,
particularly neutropenia and its consequences. In this study of
S-1 cisplatin, the incidence of grade 3 or 4 neutropenia was
28%, lower than that observed with established therapy
regimens of cisplatin/paclitaxel (75%) or cisplatin/docetaxel
(69%).25 The incidence of death due to toxicity (3 of 58, 5%)
observed in this study is consistent with that observed with
other established regimens in advanced NSCLC, including
cisplatin  taxanes therapies.22
While the S-1  cisplatin regimen is active, the initial
impression from this multicenter phase II trial is that it is
unlikely to be superior to currently approved platinum-dou-
blet regimens, which are currently administered in North
America. For this reason, the present regimen would not be
taken forward into a phase III trial. However, there is evi-
dence that S-1 may be synergistic with other agents as well:
preclinical data indicates that the epidermal growth factor
receptor tyrosine kinase inhibitor gefitinib may enhance S-1
activity via downregulation of TS activity.33 In addition, the
combination of S-1 and docetaxel exhibited downregulation
of both DPD and TS and did so to a greater extent than the
combination of docetaxel and 5-FU.34 An additional report
suggests that histone deacetylase inhibitors may at least
partially reverse fluoropyrimidine resistance by downregulat-
ing TS expression, although it is unclear whether this will
enhance S-1 activity specifically.35
In summary, S-1 alone, and in combination with cis-
platin, appears to be active in NSCLC. This is similar to the
findings of Japanese investigators. In Japan, a phase III trial
is being conducted by comparing S-1  cisplatin versus
cisplatin docetaxel as first-line therapy for the patients with
advanced NSCLC.36 It also appears that the S-1 contributes
activity in this regimen, as the platinums that are currently
available in North America (cisplatin and carboplatin) actu-
ally have very limited activity as single agents in this disease.
While this combination appears to be a potential treatment
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regimen for the population of patients with NSCLC, this
doublet does not appear to be superior to other platinum-
based doublet regimens. However, in light of a growing body
of data of other agents, which are already used for the therapy
for NSCLC and may be associated with true synergy, further
in vitro and clinical evaluation of S-1 is warranted to deter-
mine the potential optimal treatment regimen in this spectrum
of diseases.
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